Nanobiotix Launches Global Follow-On Offering

Nanobiotix, the biotechnology firm listed on Euronext and NASDAQ, announced the launch of a global follow-on offering aimed at raising approximately €75 million. This offering involves the issuance of American Depositary Shares (ADSs) in the United States and ordinary shares along with pre-funded warrants in Europe. The company aims to leverage this offering to further its pioneering work in cancer treatment and major diseases.

The proceeds are earmarked for advancing the Nanoprimer and related platforms (50-60%), ongoing development of JNJ-1900 (NBTXR3) (less than 10%), and general corporate purposes (30-40%). Notably, the securities to be issued will not bear preferential subscription rights for existing shareholders.

Jefferies, TD Cowen, and Stifel are the appointed global coordinators. The exact pricing and total amount offered will be determined following a book-building process. The offering price in the U.S. will reflect the euro price in the International Offering, converted to dollars.